Profile: Lundbeck Inc. is a fully integrated global pharmaceutical company. We advance medicines by developing, manufacturing and marketing medically necessary branded pharmaceutical products that satisfy unmet medical needs. We concentrate on CNS, hematology, oncology and hospital products. Our product elspar® is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia. Elspar is an enzyme used as adjunctive therapy in the hospital setting. Our product Mustargen® administered intravenously, is indicated for the palliative treatment of Hodgkin's disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma. It is available in vials containing 10 mg of mechlorethamine hydrochloride triturated with sodium chloride. Mustargen is a biologic alkylating agent in the group of medicines known as antineoplastics. Our product Panhematin® is indicated for the amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women. It is an enzyme inhibitor derived from processed red blood cells.